Autologous vs. Allogeneic CAR T
The Moffitt Medical Minute is a weekly video series featuring Moffitt Cancer Center President and CEO Dr. Patrick Hwu. He takes complex or confusing medical and scientific topics and breaks them down in just 60 seconds.
Autologous CAR T-cell therapy uses a patient’s own immune cells while allogeneic, or off-the-shelf, CAR T-cell therapy uses T cells from donor blood or sometimes umbilical cord blood.
Watch this episode of the Moffitt Medical Minute to learn about the differences between autologous and allogeneic CAR T-cell therapy.
